BMRN - FDA approves use of BioMarin drug Voxzogo in children under 5
2023-10-20 17:21:59 ET
More on BioMarin Pharmaceutical
- BioMarin: Growth Drivers Remain Intact
- BioMarin: Q2 2023 Confirmed My Bullish View
- Biomarin Pharmaceutical, Inc. (BMRN) Q2 2023 Earnings Call Transcript
- BioMarin a market perform at Raymond James due to growth concerns
- Seeking Alpha’s Quant Rating on BioMarin Pharmaceutical
For further details see:
FDA approves use of BioMarin drug Voxzogo in children under 5